Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330. https://doi.org/10.1056/NEJMoa1412082

Article  CAS  PubMed  Google Scholar 

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E et al (2019) Nivolumab plus Ipilimumab in advanced non-small-cell lung Cancer. N Engl J Med 381(21):2020–2031. https://doi.org/10.1056/NEJMoa1910231

Article  CAS  PubMed  Google Scholar 

Tiu C, Wong A, Herschtal A, Mileshkin L (2018) Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers. Asia Pac J Clin Oncol 14(4):337–342. https://doi.org/10.1111/ajco.12867

Article  PubMed  Google Scholar 

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA et al (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20(10):1370–1385. https://doi.org/10.1016/S1470-2045(19)30413-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hahn AW, Gill DM, Agarwal N, Maughan BL (2017) PD-1 checkpoint inhibition: toxicities and management. Urol Oncol 35(12):701–707. https://doi.org/10.1016/j.urolonc.2017.08.005

Article  CAS  PubMed  Google Scholar 

Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148. https://doi.org/10.1016/j.ejca.2015.11.016

Article  CAS  PubMed  Google Scholar 

Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559–574. https://doi.org/10.1093/annonc/mdv623

Article  CAS  PubMed  Google Scholar 

Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51–60. https://doi.org/10.1016/j.ctrv.2016.02.001

Article  CAS  PubMed  Google Scholar 

Gong J, Chehrazi-Raffle A, Reddi S, Salgia R (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6(1):8. https://doi.org/10.1186/s40425-018-0316-z

Article  PubMed  PubMed Central  Google Scholar 

Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL (2020) Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep 22(4):39. https://doi.org/10.1007/s11912-020-0897-9

Article  PubMed  Google Scholar 

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer 5(1):95. https://doi.org/10.1186/s40425-017-0300-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang L, Wang J, Lin N, Zhou Y, He W, Liu J, Ma X (2021) Immune checkpoint inhibitor-associated colitis: from mechanism to management. Front Immunol 12:800879. https://doi.org/10.3389/fimmu.2021.800879

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2(10):1346–1353. https://doi.org/10.1001/jamaoncol.2016.1051

Article  PubMed  Google Scholar 

Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and Meta-analysis. JAMA Oncol 4(2):173–182. https://doi.org/10.1001/jamaoncol.2017.3064

Article  PubMed  Google Scholar 

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563–580. https://doi.org/10.1038/s41571-019-0218-0

Article  CAS  PubMed  Google Scholar 

Bello E, Cohen JV, Mino-Kenudson M, Dougan M (2019) Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. J Immunother Cancer 7(1):41. https://doi.org/10.1186/s40425-019-0524-1

Article  PubMed  PubMed Central  Google Scholar 

Obeidat A, Silangcruz K, Kozai L, Wien E, Fujiwara Y, Nishimura Y (2022) Clinical characteristics and outcomes of gastritis associated with immune checkpoint inhibitors: scoping review. J Immunother 45(8):363–369. https://doi.org/10.1097/CJI.0000000000000435

Article  CAS  PubMed  Google Scholar 

Placke JM, Rawitzer J, Reis H, Rashidi-Alavijeh J, Livingstone E, Ugurel S et al (2021) Apoptotic gastritis in melanoma patients treated with PD-1-based immune checkpoint inhibition - clinical and histopathological findings including the diagnostic value of anti-Caspase-3 immunohistochemistry. Front Oncol 11:725549. https://doi.org/10.3389/fonc.2021.725549

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johncilla M, Grover S, Zhang X, Jain D, Srivastava A (2020) Morphological spectrum of immune check-point inhibitor therapy-associated gastritis. Histopathology. 76(4):531–539. https://doi.org/10.1111/his.14029

Article  PubMed  Google Scholar 

Onuki T, Morita E, Sakamoto N, Nagai Y, Sata M, Hagiwara K (2018) Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient. Respirol Case Rep 6(6):e00334. https://doi.org/10.1002/rcr2.334

Article  PubMed  PubMed Central  Google Scholar 

Stummvoll GH, DiPaolo RJ, Huter EN, Davidson TS, Glass D, Ward JM, Shevach EM (2008) Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J Immunol 181(3):1908–1916. https://doi.org/10.4049/jimmunol.181.3.1908

Article  CAS  PubMed  Google Scholar 

Huter EN, Stummvoll GH, DiPaolo RJ, Glass DD, Shevach EM (2009) Pre-differentiated Th1 and Th17 effector T cells in autoimmune gastritis: ag-specific regulatory T cells are more potent suppressors than polyclonal regulatory T cells. Int Immunopharmacol 9(5):540–545. https://doi.org/10.1016/j.intimp.2009.01.022

Article  CAS  PubMed  Google Scholar 

Bockerstett KA, DiPaolo RJ (2017) Regulation of gastric carcinogenesis by inflammatory cytokines. Cell Mol Gastroenterol Hepatol 4(1):47–53. https://doi.org/10.1016/j.jcmgh.2017.03.005

Article  PubMed  PubMed Central  Google Scholar 

Ferrian S, Liu CC, McCaffrey EF, Kumar R, Nowicki TS, Dawson DW, Baranski A, Glaspy JA, Ribas A, Bendall SC, Angelo M (2021) Multiplexed imaging reveals an IFN-γ-driven inflammatory state in nivolumab-associated gastritis. Cell Rep Med 2(10):100419. https://doi.org/10.1016/j.xcrm.2021.100419

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17):1714–1768. https://doi.org/10.1200/JCO.2017.77.6385

Article  CAS  PubMed  Google Scholar 

Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K (2018) ESMO guidelines committee. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv264–iv266. https://doi.org/10.1093/annonc/mdy162

Article  CAS  PubMed  Google Scholar 

Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F et al (2016) Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 10(4):395–401. https://doi.org/10.1093/ecco-jcc/jjv227

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gaffuri P, Espeli V, Fulciniti F, Paone G, Bergmann M (2019) Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy. Pathologica 111(3):92–97. https://doi.org/10.32074/1591-951X-24-19

Article  CAS  PubMed  PubMed Central  Google Scholar